BEDFORD, Mass., June 18, 2015 /PRNewswire/ -- Hologic, Inc.
(NASDAQ: HOLX) announced today that it has launched, subject to
market and other conditions, a private offering of $1.0 billion aggregate principal amount of its
senior notes due 2022. Hologic intends to use the proceeds of the
offering, plus available cash, to redeem its outstanding 6.25%
senior notes due 2020 in the aggregate principal amount of
$1.0 billion.
The 2022 notes will not be registered under the Securities Act
of 1933, as amended, or any state securities laws. Unless so
registered, the securities may not be offered or sold in
the United States except pursuant
to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and applicable
state securities laws. The 2022 notes are being offered only
to qualified institutional buyers in reliance on Rule 144A under
the Securities Act, and outside the
United States in accordance with Regulation S under the
Securities Act.
Hologic will redeem the 2020 notes on August 1, 2015, subject to the completion of the
offering and the receipt of its proceeds, for an aggregate
redemption price of $1.03125
billion. In addition, Hologic will make a final
interest payment in the amount of $31.25
million for interest accrued to August 1, 2015, to holders of record of the 2020
notes as of July 15,
2015.
This press release is neither an offer to sell nor a
solicitation of an offer to buy any of these securities, nor
shall there be any offer, solicitation or sale of these
securities in any jurisdiction where the offer, solicitation or
sale is not permitted. This press release shall not constitute a
notice of redemption with respect to the 6.25% senior notes due
2020.
Forward-Looking Statements
This press release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions. Such
statements include, without limitation, the Company's intention to
issue the 2022 notes in a private placement pursuant to Rule 144A
under the Securities Act of 1933, and outside the United States in accordance with
Regulation S under the Securities Act, and to redeem the 2020 notes
using the proceeds of the offering. These forward-looking
statements are subject to known and unknown risks and uncertainties
that could cause actual results to differ materially from those
expressed or implied by such statements. The offering and/or the
redemption may also be adversely affected by prevailing credit
markets, which have been subject to significant volatility, or
adverse changes to Hologic's business or prospects. Hologic cannot
assure it will complete the issuance of the 2022 notes, or the
redemption, on favorable terms, if at all. The risks included above
are not exhaustive. Other factors that could adversely affect the
Company's business and prospects are described in the filings made
by Hologic with the SEC. Hologic expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such statements are based.
Contact
Michael Watts
Vice President, Investor Relations and
Corporate Communications
(858) 410-8588
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-announces-offering-of-10-billion-of-senior-notes-due-2022-300101295.html
SOURCE Hologic, Inc.